Uncategorized-EN
Cabozantinib in High Grade Uterine Sarcoma (HGUtS)
Maintenance therapy with Cabozantinib in High Grade Uterine Sarcoma (HGUtS) Agents: Cabozantinib Phase II Status Open, recruiting Sponsor EORTC Further information: https://clinicaltrials.gov/ct/show/NCT01979393 or http://www.eortc.org/research_field/clinical-detail/62113/ A phase II study evaluating the role of maintenance therapy with Cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to chemotherapy WHO is the trial for?…
Read MoreMilademetan versus trabectedin in dedifferentiated liposarcoma (MANTRA)
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA) Agents: Milademetan vs. Trabectedin Phase III Status Recruiting Sponsor Rain Therapeutics Inc. Further information: https://www.clinicaltrials.gov/ct2/show/NCT04979442?term=mantra&cond=sarcoma&draw=2&rank=1 This is a Phase 3 registration study evaluating the safety and efficacy of milademetan compared to trabectedin in patients with unresectable or metastatic, progressing dedifferentiated liposarcoma. WHO is the…
Read MoreNavigator: Avapritinib (BLU-285)
NAVIGATOR: Avapritinib (BLU-285) Phase I study of Avapritinib (formerly BLU-285) in patients with GIST and other relapsed/refractory solid tumors (Navigator). Trial name: Navigator Agents: Avapritinib (formerly BLU-285) Phase I Status Completed Sponsor Blueprint Medicines Corporation Further information: https://www.clinicaltrials.gov/ct2/show/NCT02508532?term=NCT02508532&rank=1 WHO is the trial for? Patients with GIST that has progressed following imatinib and at least 1…
Read MoreVimseltinib for Tenosynovial Giant Cell Tumor (MOTION)
Trial name: Vimseltinib for Tenosynovial Giant Cell Tumor (TGCT), MOTION study Agents: Vimseltinib vs. placebo Phase III Status Not recruiting, but active Sponsor Deciphera Pharmaceuticals This Phase 3 clinical study aims to evaluate the effectiveness of vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the…
Read MoreANITA
ANITA – Nintedanib with Ifosfamide in advanced, metastatic Soft Tissue Sarcoma (STS) Agents: Nintedanib vs. Ifosfamide Phase II Status Closed, active Sponsor EORTC in collaboration with Boehringer Ingelheim Further information: https://clinicaltrials.gov/ct/show/NCT02808247 or http://www.eortc.org/research_field/clinical-detail/1506/ A Phase II study comparing Nintedanib with Ifosfamide in patients with advanced, metastatic Soft Tissue Sarcoma (STS) after failure…
Read MorePalbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Ewing Sarcomas
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors incl. Ewing Sarcomas (phase II) Agents: Combination with irinotecan and temozolomide with or without palbociclib Phase II Status Closed for recruitment, but active Sponsor Pfizer Further information: https://clinicaltrials.gov/ct2/show/NCT03709680 This study is comparing the effectiveness of the study medicine palbociclib when taken in combination with chemotherapy medicines irinotecan…
Read MoreTrabectedin Maintenance
Trabectedin Maintenance post 1st-line in STS Agents: Trabectedin Phase III Status Open, recruiting Sponsor EORTC in collaboration with PharmaMar Further information: https://clinicaltrials.gov/ct/show/NCT02929394 or http://www.eortc.org/research_field/clinical-detail/1447/ Maintenance therapy with Trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma WHO is the trial for? Adult patients (18 years…
Read MoreDose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas (DOREMY)
Agents: Radiotherapy Phase II Status Closed, active Sponsor The Netherlands Cancer Institute Further information: https://clinicaltrials.gov/ct2/show/NCT02106312 WHO is the trial for? Adult patients with confirmed Myxoid Liposarcoma (MLS) of the soft tissue without metastasis or with only a small number of metastasis (oligometastasis) Overall health status of the patient has to be good (ECOG…
Read Moreinvictus: DCC-2618 vs. placebo in advanced pre-treated GIST patients
Agents: DCC-2618 vs. placebo Phase III Status Closed, active Sponsor Deciphera Pharmaceuticals LLC Further information: https://clinicaltrials.gov/ct2/show/NCT03353753 WHO is the trial for? Patients with confirmed advanced or metastatic GIST with all types of mutation in KIT or PDGFRa (excluded are patients without KIT or PDGFRa mutations) Patients must have progressed on imatinib, sunitinib,…
Read MorerEECur
Trial for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Agents: Four different chemotherapy regimens Phase II/III Status Open, recruiting Sponsor University of Birmingham Further information can be found here. WHO is the trial for? Patients with Ewing sarcoma that has come back after treatment Patients with primary Ewing sarcoma that is…
Read More